On January 5, 2024, Avidity Biosciences, Inc. announced that Eric Mosbrooker has resigned from the company's board of directors (the board) and the Human Capital Management Committee of the Board (the Committee), effective as of December 31, 2023. Mr. Mosbrooker's resignations from the Board and the Committee were not made in connection with a disagreement between the company and Mr. Mosbrooker on any matter relating to the company's operations, policies or practices. Effective January 1, 2024, Mr. Mosbrooker will serve the company as a non-executive employee in the newly created position of chief strategy officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.36 USD | +2.22% | +7.17% | +169.17% |
Apr. 04 | Avidity Biosciences Insider Sold Shares Worth $734,919, According to a Recent SEC Filing | MT |
Apr. 04 | Avidity Biosciences Insider Sold Shares Worth $542,214, According to a Recent SEC Filing | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+169.17% | 2.33B | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.35B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- RNA Stock
- News Avidity Biosciences, Inc.
- Avidity Biosciences, Inc. Announces Resignation of Eric Mosbrooker as Board of Directors and the Human Capital Management Committee of the Board